MEGA BIOPHARMA — HomeFRContact

Portfolio & development

Biomaterials.
Multiple opportunities.

Two distinct dental ranges: nacre-derived Bionacre® and Ostenova, which brings together a porcine-derived bone substitute and collagen membranes.

Our dental ranges

Bionacre® & Ostenova.
Two distinct ranges.

Bionacre® is developed from nacre. Ostenova brings together a porcine-derived bone substitute and collagen membranes. Each product follows its own pathway.

Nacre granules from the Bionacre Bone Graft programme

Nacre-derived range

Bionacre®
Bone Graft.

Our nacre-derived bone substitute programme, developed for filling bone defects in dental surgery.

In development · late preclinical stage

Explore the Bionacre® programme

Bone substitute & membranes

Ostenova.

A dental range in its own right.

Coming soon

Bone substitute

Ostenova Bone Graft — Granules · 0.5 cc
Granules · 0.5 cc0,25–1,0 mm
Ostenova Bone Graft — Granules · 2.0 cc
Granules · 2.0 cc1,0–2,0 mm
Ostenova Bone Graft — Syringe · 0.5 cc
Syringe · 0.5 cc0,25–1,0 mm

A porcine-derived bone substitute within the Ostenova range.

Contact the product team
Launch planned for late 2026

Collagen membranes

Resorbable porcine collagen membranes in three sizes.

Discover the membranes
Ostenova Membrane — packaging 30 × 40 mm

BIONACRE® BONE GRAFT / PROGRAMME STATUS

From preclinical development
to the next milestones.

CURRENT STAGE

Late preclinical stage

Bionacre® Bone Graft is in the final stage of preclinical development.

EUROPE

Clinical investigation

Applications to conduct a clinical investigation in Europe are being prepared.

UNITED STATES · EARLY 2027

Planned 510(k) submission

A submission to the FDA is planned for early 2027. This milestone is prospective.

Status communicated by MEGA BIOPHARMA in September 2026. Submitting a dossier does not constitute market authorisation.

Bionacre® platform opportunities

From bone
to cartilage.

One technology foundation, several research directions. Each application requires its own development and assessments.

Orthopaedics

Bone repair & fixation

Machined components, compact forms and potential applications in extremities, trauma and spine.

Research direction

Cartilage

Injectable formulations

Nacre-derived materials to explore cartilage and osteochondral repair, including injectable formats.

Research direction

Maxillofacial surgery

New reconstruction needs

Opportunities to evaluate with clinical and industrial partners.

Research direction

An application already on the market

Blue Skincare

Alongside our bone-regeneration programmes, our expertise in nacre has led to a dermo-cosmetic range already on the market.

Visit the e-shop ↗

Customer satisfaction

4.9/5

More than 900 verified reviews reported by Blue Skincare: a rating that reflects strong satisfaction with the skincare products.

Read customer reviews ↗Rating displayed on the Blue Skincare website, accessed 1 October 2026. Feedback on cosmetic skincare products.

Let’s discuss your project

Let’s move
research forward.

Contact our team

MEGA BIOPHARMA

Cookies &
privacy.

This site does not include advertising, audience analytics or cross-site tracking tools.

Videos and fonts
Hosted with the site. No YouTube player or social media widget is loaded during your visit.
Your preference
If you click “Got it”, your browser stores only the dismissal of this notice for six months in local storage. This preference is not sent to a server.
Contacting us
The form prepares an email in your email application. It does not send your fields to a server from this page. Links to external sites lead to their own privacy policies.

For questions about your data: dpo@megabiopharma.com